• Combinational Targeting of eIF4F, AKT1, and EZH2 in BRAFV600

  2026-05-18

  This study investigates how combinational inhibition of the eIF4F complex, AKT1, and EZH2 overcomes resistance to targeted therapies in BRAFV600E-mutant melanoma cells. The findings elucidate the signaling dynamics underlying resistance and suggest a rational strategy for enhancing anticancer efficacy in melanoma models.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Enhanced Immunotherapy Workf

  2026-05-17

  EZ Cap™ Mouse IL-12 mRNA (m1Ψ) empowers researchers to drive efficient, low-immunogenicity cytokine expression in advanced immunotherapy and gene expression studies. By leveraging virus-mimicking nanoparticle delivery and cutting-edge mRNA modifications, this reagent offers a robust, reproducible platform for targeting extrahepatic tissues and overcoming standard delivery barriers.

• Lopinavir (ABT-378) in HIV Protease and Antiviral Assays

  2026-05-16

  Lopinavir (ABT-378), a potent HIV protease inhibitor from APExBIO, offers unique advantages for both traditional HIV research and emerging antiviral applications. Its serum-stable activity and resistance resilience empower researchers to design robust inhibition assays and explore cross-pathogen antiviral strategies.

• Isoprinosine: Immunomodulation and Viral Inhibition Workflow

  2026-05-15

  Isoprinosine (inosine pranobex) uniquely bridges immune enhancement and direct antiviral action, empowering research in both viral replication inhibition and acute respiratory infection models. This guide translates recent breakthroughs—like the identification of CLCC1’s role in herpesvirus egress—into actionable protocols, troubleshooting insights, and workflow upgrades for advanced immunotherapy assays.

• Nanomedicine Synergizes Bufalin and CRISPR/Cas9 for CRC Immu

  2026-05-15

  This study introduces a calcium lactate nanoparticle system that co-delivers bufalin and CRISPR/Cas9 ribonucleoproteins, targeting both tumor cell death and immune microenvironment remodeling in colorectal cancer. The strategy induces pyroptosis, promotes M1 macrophage polarization, and enhances immunotherapeutic efficacy—offering an innovative multimodal approach with translational potential.

• Cy3 TSA Fluorescence System Kit: Advancing Lipid Metabolism

  2026-05-14

  Explore how the Cy3 TSA Fluorescence System Kit empowers ultrasensitive detection of lipid metabolic pathways in cancer research. This article uniquely connects signal amplification in immunohistochemistry to breakthroughs in tumor biology and assay optimization.

• Escitalopram in Antidepressant Research: Protocols & Trouble

  2026-05-14

  Escitalopram, the S-(+)-enantiomer of citalopram, enables highly selective modulation of serotonergic pathways in depression and anxiety models. This guide delivers actionable protocols, troubleshooting advice, and practical insights—grounded in peer-reviewed data and advanced by APExBIO’s high-purity formulation—to maximize reproducibility in bench-based antidepressant research.

• SAR131675: Selective VEGFR-3 Inhibition for Lymphatic Resear

  2026-05-13

  Explore SAR131675, a potent VEGFR-3 inhibitor, as a next-generation tool for dissecting lymphangiogenesis and tumor biology. This article uniquely bridges advanced kinase selectivity with translational assay insights, distinguishing SAR131675 in preclinical research.

• Homoharringtonine: Cytotoxic Alkaloid Empowering Cancer and

  2026-05-13

  Homoharringtonine, a potent cytotoxic alkaloid from APExBIO, is transforming both leukemia and antiviral experimental workflows by targeting ribosomal protein synthesis. This article details robust, evidence-based protocols, troubleshooting strategies, and the newest cross-domain insights—including rapid SARS-CoV-2 clearance—supported by recent peer-reviewed breakthroughs.

• CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Ce

  2026-05-12

  The CFDA SE Cell Tracer Kit provides researchers with a robust solution for long-term, stable fluorescent labeling of live cells, supporting cell lineage tracing and cell proliferation studies with minimal cytotoxicity. It is best suited for workflows needing durable covalent staining and is not appropriate for reversible or short-term cell labeling applications.

• Evaluating Drug Responses in Cancer: Advances in In Vitro Me

  2026-05-12

  Schwartz’s dissertation critically addresses the limitations of conventional in vitro drug response assays in cancer research, distinguishing between proliferative arrest and cell death. The work proposes refined methodologies to more accurately characterize anticancer compound effects, informing better experimental design and interpretation for preclinical studies.

• Guanabenz Acetate: Bridging α2-Adrenergic and Innate Immunit

  2026-05-11

  This thought-leadership article explores the mechanistic and translational potential of Guanabenz Acetate as a selective α2-adrenergic receptor agonist. Integrating evidence from neurobiology, GPCR signaling, and cutting-edge studies on viral immune evasion, we provide strategic insights for translational researchers. Novel connections are made to the modulation of stress granule pathways in the context of SARS-CoV-2, highlighting new opportunities for precision modulation in neuroscience and immuno-therapeutics.

• Sulfaphenazole Restores Endothelial Vasodilation in Diabetic

  2026-05-11

  This study uncovers the role of CYP2C-derived oxidative stress in diabetic vascular dysfunction and demonstrates that Sulfaphenazole, as a selective CYP2C9 inhibitor, can restore endothelium-dependent vasodilation in diabetic mice. Findings highlight a mechanistic link between cytochrome P450-mediated reactive oxygen species and impaired nitric oxide signaling, with translational implications for vascular research.

• MLN4924 HCl Salt: NEDD8 Inhibition, Viral Immunity, and Assa

  2026-05-10

  Explore the advanced utility of MLN4924 HCl salt as a NEDD8-activating enzyme inhibitor. This article uniquely connects neddylation pathway inhibition to viral immune evasion and provides protocol-level guidance for next-generation research.

• Structure-Based Screening Reveals NSP15 Inhibitors in SARS-C

  2026-05-09

  This study identifies thymopentin and oleuropein as potent inhibitors of the SARS-CoV-2 NSP15 endoribonuclease using structure-based virtual screening and molecular dynamics simulations. The findings provide key insights for antiviral drug discovery targeting viral immune evasion mechanisms and highlight computational approaches as valuable tools for rapid inhibitor identification.

15608 records 1/1041 page Next 12345 下5页 Last page